Abbott Laboratories's results for Q3 2026 (ended Sep 30, 2026) come from the company's own earnings release, filed with the SEC on 2026-10-21. Everything below is taken from that filing; quotes are copied exactly. Company outlooks are the company's own.
At a glance
| Item | Value |
|---|---|
| Revenue (GAAP) | $13,013 million (+14.5% vs a year earlier) |
| Diluted EPS (GAAP) | $0.53 |
| Adjusted per-share figure (company's non-GAAP measure; FFO/AFFO for REITs) | $1.42 |
| Full-year guidance | Narrowed |
Guidance
Tightened 2026 adjusted EPS range to $5.50–$5.55 with midpoint reaffirmed; projects about 6.0% comparable sales growth; Q4 adjusted EPS $1.62–$1.67.
Why this label: Reaffirms midpoint of prior adjusted EPS range and tightens it to $5.50-$5.55; ~6% comparable sales growth stated without change wording.
| Metric | Period | New | Prior (as stated in the release) |
|---|---|---|---|
| adjusted diluted EPS | FY2026 | $5.50–$5.55 | not stated |
| comparable sales growth | FY2026 | approximately 6.0% | not stated |
Next-quarter outlook:
| Metric | Period | Range |
|---|---|---|
| adjusted diluted EPS | Q4 2026 | $1.62–$1.67 |
From the release
Revenue: "Third-quarter sales increased 14.5 percent on a reported basis and 7.0 percent on a comparable basis."
Earnings per share: "Third-quarter GAAP diluted EPS of $0.53 and adjusted diluted EPS of $1.42, which excludes specified items."
adjusted diluted EPS: "Abbott reaffirms the midpoint of previously provided full-year 2026 adjusted diluted EPS guidance range and tightens the range to $5.50 to $5.55."
comparable sales growth: "Abbott projects full-year 2026 comparable sales growth to be approximately 6.0%"
Key fact: Q3 reported sales up 14.5%, comparable 7.0%; 2026 adjusted EPS range tightened to $5.50–$5.55.
Source
Abbott Laboratories earnings release (SEC filing), accession 0001628280-26-066601, filed 2026-10-21.
Part of the Q3 2026 Guidance Tracker. Educational only, not advice. Free weekly recap every Sunday: yieldterminalpro.com/newsletter.